Edition:
India

Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

20.32USD
22 Apr 2019
Change (% chg)

-- (--)
Prev Close
$20.32
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
584,690
52-wk High
$53.90
52-wk Low
$11.50

Latest Key Developments (Source: Significant Developments)

Clovis Oncology Says Discontinuing Phase 2 Monotherapy Clinical Trial Evaluating Rucaparib In Bladder Cancer
Saturday, 13 Apr 2019 

April 12 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY - DISCONTINUING SPONSORED PHASE 2 OPEN-LABEL MONOTHERAPY CLINICAL TRIAL EVALUATING RUCAPARIB IN RECURRENT, METASTATIC BLADDER CANCER.CLOVIS - DISCONTINUATION DECISION BASED ON RECOMMENDATIONS BY INDEPENDENT DMC AFTER REVIEW OF PRELIMINARY EFFICACY DATA FOR 62 PATIENTS IN STUDY.CLOVIS- PRELIM DATA IN STUDY DEMONSTRATED OBJECTIVE RESPONSE RATE IN INTENT-TO-TREAT POPULATION DOES NOT MEET PROTOCOL-DEFINED CONTINUANCE CRITERIA.CLOVIS - PRELIMINARY DATA IN STUDY SUGGESTS TREATMENT WITH MONOTHERAPY RUCAPARIB MAY NOT PROVIDE MEANINGFUL CLINICAL BENEFIT TO PATIENTS.CLOVIS ONCOLOGY INC - DMC RECOMMENDED TO STOP ENROLLMENT TO STUDY, AND CLOVIS HAS DECIDED TO TERMINATE ATLAS TRIAL EARLY.CLOVIS ONCOLOGY INC - RECOMMENDATION OF DMC WAS NOT BASED ON SAFETY PROFILE OF RUCAPARIB IN THIS STUDY POPULATION.CLOVIS ONCOLOGY INC - CONTINUING TO EVALUATE POTENTIAL FOR RUCAPARIB IN COMBINATION WITH OTHER AGENTS FOR TREATMENT OF ADVANCED BLADDER CANCER.CLOVIS - TO ENROLL PATIENTS WITH ADVANCED BLADDER CANCER & SELECTED GENETIC MUTATIONS IN PLANNED PAN-TUMOR TRIAL OF RUCAPARIB EXPECTED TO START H2 2019.  Full Article

Alkermes And Clovis Oncology Initiate Research Collaboration To Explore Combination Cancer Therapies
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Clovis Oncology Inc ::ALKERMES AND CLOVIS ONCOLOGY INITIATE RESEARCH COLLABORATION TO EXPLORE COMBINATION CANCER THERAPIES.CLOVIS ONCOLOGY- ALKERMES, CO TO EXAMINE COMBINATIONS OF ALKS 4230 WITH RUCAPARIB & ALKS 4230 WITH LUCITANIB IN MULTIPLE MODELS IN PRECLINICAL STUDIES.CLOVIS ONCOLOGY INC - COMPANIES WILL SHARE COSTS RELATED TO PRECLINICAL STUDIES.  Full Article

Alkermes And Clovis Oncology Initiate Research Collaboration To Explore Combination Cancer Therapies
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Alkermes Plc ::ALKERMES AND CLOVIS ONCOLOGY INITIATE RESEARCH COLLABORATION TO EXPLORE COMBINATION CANCER THERAPIES.CLOVIS ONCOLOGY INC - COMBINATIONS OF ALKS 4230 WITH RUCAPARIB AND LUCITANIB TO BE EVALUATED IN MULTIPLE PRECLINICAL TUMOR MODELS.CLOVIS - COMPANIES WILL SHARE COSTS RELATED TO PRECLINICAL STUDIES, AND EACH WILL CONTRIBUTE THEIR RESPECTIVE COMPOUNDS TO RESEARCH COLLABORATION..  Full Article

Armistice Capital Reports 9.8 Pct Stake In Clovis Oncology As Of Oct 24
Tuesday, 6 Nov 2018 

Nov 5 (Reuters) - Clovis Oncology Inc ::ARMISTICE CAPITAL, LLC REPORTS 9.8 PERCENT STAKE IN CLOVIS ONCOLOGY INC AS OF OCTOBER 24 - SEC FILING.ARMISTICE CAPITAL SAYS PURCHASED SHARES ON BELIEF CLOVIS ONCOLOGY'S SHARES, WHEN PURCHASED, WERE UNDERVALUED.  Full Article

Clovis Oncology Reports Q3 Loss Per Share Of $1.71
Wednesday, 31 Oct 2018 

Oct 30 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES THIRD QUARTER 2018 OPERATING RESULTS.Q3 LOSS PER SHARE $1.71.Q3 EARNINGS PER SHARE VIEW $-1.60 -- THOMSON REUTERS I/B/E/S.COMPANY ANTICIPATES Q4 2018 REVENUES TO BE CONSISTENT WITH OR SLIGHTLY HIGHER THAN Q3 2018.ANTICIPATES PROVIDING FULL-YEAR 2019 GUIDANCE IN EARLY JANUARY..  Full Article

Clovis Oncology Announces European Commission Authorization Of Rubraca
Tuesday, 29 May 2018 

May 29 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES EUROPEAN COMMISSION AUTHORIZATION OF RUBRACA® (RUCAPARIB) FOR WOMEN WITH RECURRENT OVARIAN CANCER.CLOVIS ONCOLOGY INC - EC APPROVAL WAS BASED ON DATA FROM TWO MULTICENTER, SINGLE-ARM, OPEN-LABEL CLINICAL TRIALS.  Full Article

Clovis Oncology Reports Q1 Loss Per Share $1.54
Wednesday, 9 May 2018 

May 8 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES FIRST QUARTER 2018 OPERATING RESULTS.Q1 LOSS PER SHARE $1.54.Q1 EARNINGS PER SHARE VIEW $-1.36 -- THOMSON REUTERS I/B/E/S.QTRLY PRODUCT REVENUE $18.5 MILLION VERSUS $7 MILLION.  Full Article

Clovis Oncology Says SEC Issued 'Wells Notices' To Co & Certain Of Its Officers
Tuesday, 10 Apr 2018 

April 10 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY SAYS ON APRIL 9 SEC ISSUED 'WELLS NOTICES' TO CO & CERTAIN OF ITS CURRENT AND FORMER OFFICERS - SEC FILING.SEC'S 'WELLS NOTICES' ALLEGES VIOLATIONS OF SOME PROVISIONS OF SECURITIES ACT OF 1933 AND SECURITIES EXCHANGE ACT OF 1934.ALLEGED VIOLATIONS RELATE TO CO'S REGULATORY UPDATE IN NOV 2015 THAT FDA REQUESTED MORE CLINICAL DATA ON EFFICACY, SAFETY OF ROCILETINIB.  Full Article

EMA Panel Recommends Conditional Approval Of Clovis Oncology Ovarian Cancer Drug Rubraca
Friday, 23 Mar 2018 

March 23 (Reuters) - EU Medicines Agency: :RECOMMENDS APPROVAL OF CLOVIS ONCOLOGY <<>> OVARIAN CANCER DRUG RUBRACA.EU MEDICINES AGENCY SAYS RECOMMENDED GRANTING A CONDITIONAL MARKETING AUTHORISATION FOR CLOVIS OVARIAN CANCER DRUG RUBRACA.  Full Article

Clovis Oncology Q4 Adjusted Loss Per Share $1.27
Tuesday, 27 Feb 2018 

Feb 26 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES 2017 OPERATING RESULTS.Q4 ADJUSTED LOSS PER SHARE $1.27 EXCLUDING ITEMS.Q4 LOSS PER SHARE $1.04.QTRLY ‍​NET PRODUCT REVENUE $17 MILLION VERSUS $78,000.Q4 REVENUE VIEW $20.1 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Clovis Oncology halts mid-stage bladder cancer trial, shares drop

Clovis Oncology Inc said on Friday it was halting a mid-stage trial testing its lead drug in bladder cancer patients, sending shares down 12 percent.